Today, Edgewater Ranzal announced that it has been recognized by the Commonwealth Institute and Moore Research as the third largest woman-led business in South Florida. Edgewater Ranzal is a wholly-owned subsidiary of Edgewater Technology.
Edgewater Ranzal was recognized at the 8th Annual Awards Ceremony and Luncheon on March 19th at Jungle Island. The ceremony, which includes a luncheon and silent auction, honors South Florida’s top women-led businesses and top women leaders. This isn’t the first time Edgewater Ranzal has been honored by the Commonwealth Institute and Moore Research; the company was recognized as the eighth largest women-led business in 2011, but has since climbed to the number three spot.
Robin Ranzal-Knowles, the company’s president, remarked, “I’m honored to be ranked as one of the top women-led businesses in Florida. This achievement is a reflection of the hard work, dedication, and unmatched expertise that our team brings to each and every project.”
Ms. Ranzal Knowles founded Ranzal & Associates in 1996, and has grown the organization into a premier Enterprise Performance Management consulting firm, now known as Edgewater Ranzal. Since 1996, Edgewater Ranzal has grown from a small Hyperion shop to one of the largest Oracle Platinum EPM implementation partners, with offices in the US and UK, and clients across the globe.
Ms. Ranzal Knowles is recognized as an authority on Oracle Hyperion’s Essbase (OLAP) technology. She frequent speaks at Oracle Hyperion events, including Oracle Hyperion’s User Conferences, and has served as a panel expert for Business Performance Management Magazine. She has also played crucial roles in Edgewater Ranzal’s Oracle Hyperion client implementations in the Healthcare, Consumer Packaged Goods, Finance, Insurance, and Retail industries.
For more information, visit www.edgewater.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, March 28, 2013
Why the Bubble Has Set the Stage for Loans4Less.com, Inc. (LFLS)
It was called not only the biggest bubble in real estate history, but the biggest bubble of any kind that has ever happened. It involved not only the U.S., but countries around the world, with the globalization of economic markets feeding the spread. Any time that the market value of something is based primarily upon independent price inflation not tied to corresponding changes in fundamentals, it can be termed a speculative bubble. It’s an occasional though inevitable occurrence in free markets, able to tempt even foundational institutions with the prospect of easy money. But it doesn’t take a serious student of history to recognize that every bubble is inevitably followed by some sort of crash.
In 2003, a healthy rise in U.S. real estate prices began to turn into a boom, with average new home prices jumping nearly 50% over the next three years. Then, in 2006, the inflow of money dwindled, soon turning the other way. By 2008, the outward flow had become a panic, with falling prices eventually leaving close to a quarter of all U.S. homeowners owing more on their homes than they were worth in the market. In some states, thousands of homes were simply deserted as people walked away from mortgages. Finally, in 2012, prices bottomed out, and investors, who had never gone completely away, began to pounce, purchasing and holding property as rentals and waiting for prices to go up, which they are now doing.
With some cities now seeing double-digit price gains, including parts of California, and with mortgage rates still low, the dream of home ownership has come back to life in a big way. Even those who got hit the worst are looking to jump back in. But the loan market today has little in common with that of 2006, based as it is on much stricter credit requirements.
It’s a world tailor-made for California-based Loans4Less.Com, a rapidly growing online mortgage loan brokerage. The company focuses on conforming “A” paper loans, and is actively developing a national Web-based loan origination platform for joint venture and licensing partners. The company is in a unique position, and is highly optimistic about the growth of its target market as housing bounces back, an understandable view considering the company’s total revenues for 2012 increased by approximately 64% compared to 2011.
For more information, visit www.Loans4Less.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
In 2003, a healthy rise in U.S. real estate prices began to turn into a boom, with average new home prices jumping nearly 50% over the next three years. Then, in 2006, the inflow of money dwindled, soon turning the other way. By 2008, the outward flow had become a panic, with falling prices eventually leaving close to a quarter of all U.S. homeowners owing more on their homes than they were worth in the market. In some states, thousands of homes were simply deserted as people walked away from mortgages. Finally, in 2012, prices bottomed out, and investors, who had never gone completely away, began to pounce, purchasing and holding property as rentals and waiting for prices to go up, which they are now doing.
With some cities now seeing double-digit price gains, including parts of California, and with mortgage rates still low, the dream of home ownership has come back to life in a big way. Even those who got hit the worst are looking to jump back in. But the loan market today has little in common with that of 2006, based as it is on much stricter credit requirements.
It’s a world tailor-made for California-based Loans4Less.Com, a rapidly growing online mortgage loan brokerage. The company focuses on conforming “A” paper loans, and is actively developing a national Web-based loan origination platform for joint venture and licensing partners. The company is in a unique position, and is highly optimistic about the growth of its target market as housing bounces back, an understandable view considering the company’s total revenues for 2012 increased by approximately 64% compared to 2011.
For more information, visit www.Loans4Less.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
NeoStem, Inc. (NBS) Receives Second-Year NIAID Grant Award for Developing VSEL Technology to Treat Radiation Exposure
Today, cellular therapy leader NeoStem announced that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has awarded the company the second year of a two-year grant for “Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure to Radiation Threat,” Grant Number 5R43AI098325-02. The two-year grant will total $595,252.
A peer-reviewed grant, the grant was given in support of research to be headed by NeoStem Director of Stem Cell Science Denis O. Rodgerson, Ph.D., and Mariusz Ratajczak, M.D., Ph.D., who is head of the stem cell biology program at the University of Louisville’s James Graham Brown Cancer Center and the co-inventor of VSELTM Technology.
The award will fund studies investigating the potential of very small, embryonic-like stem cells as a countermeasure for radiological and nuclear threat. The product candidate, an autologous stem cell therapy derived from a patient’s own stem cells, will be developed both as a rescue measure for patients who have been exposed to radiation through nuclear accident or terrorist threat and as a treatment for cancer patients who have undergone radiation therapy and have resultantly compromised immune systems.
Persons exposed to high doses of radiation, either through cancer treatment or nuclear exposure, have compromised immune systems that make them much more vulnerable to the virulence and infectivity of biological agents. Following radiation exposure, death can occur within one to six weeks. A rescue through stem cell transplantation is currently the only intervention that can save a fatally irradiated person. VSELs may represent an ideal cell therapy for regenerating the body’s immune system and repairing other tissues damaged by exposure to radiation, as early studies have shown that VSELs are resistant to lethal radiation, which destroys other immune system-restoring stem cells in the body. This makes post-exposure autologous treatment possible.
The grant award consisted of $295,252 for the first year of the project and now includes an additional $300,000 for the second year.
“We are very pleased that our research has met its interim requirements and been awarded its second year of funding,” said Dr. Dennis O. Rodgerson.
“NeoStem is pleased that the NIAID is continuing to fund this cutting-edge technology that we hope will reinvent the treatment landscape for acute radiation syndrome,” added NeoStem Chairman and CEO Dr. Robin L. Smith. “We also expect to file an IND with the FDA in late 2013 or early 2014 to initiate a NIH-funded human clinical study treating periodontitis with VSELTM.”
For more information about NeoStem, visit www.neostem.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
A peer-reviewed grant, the grant was given in support of research to be headed by NeoStem Director of Stem Cell Science Denis O. Rodgerson, Ph.D., and Mariusz Ratajczak, M.D., Ph.D., who is head of the stem cell biology program at the University of Louisville’s James Graham Brown Cancer Center and the co-inventor of VSELTM Technology.
The award will fund studies investigating the potential of very small, embryonic-like stem cells as a countermeasure for radiological and nuclear threat. The product candidate, an autologous stem cell therapy derived from a patient’s own stem cells, will be developed both as a rescue measure for patients who have been exposed to radiation through nuclear accident or terrorist threat and as a treatment for cancer patients who have undergone radiation therapy and have resultantly compromised immune systems.
Persons exposed to high doses of radiation, either through cancer treatment or nuclear exposure, have compromised immune systems that make them much more vulnerable to the virulence and infectivity of biological agents. Following radiation exposure, death can occur within one to six weeks. A rescue through stem cell transplantation is currently the only intervention that can save a fatally irradiated person. VSELs may represent an ideal cell therapy for regenerating the body’s immune system and repairing other tissues damaged by exposure to radiation, as early studies have shown that VSELs are resistant to lethal radiation, which destroys other immune system-restoring stem cells in the body. This makes post-exposure autologous treatment possible.
The grant award consisted of $295,252 for the first year of the project and now includes an additional $300,000 for the second year.
“We are very pleased that our research has met its interim requirements and been awarded its second year of funding,” said Dr. Dennis O. Rodgerson.
“NeoStem is pleased that the NIAID is continuing to fund this cutting-edge technology that we hope will reinvent the treatment landscape for acute radiation syndrome,” added NeoStem Chairman and CEO Dr. Robin L. Smith. “We also expect to file an IND with the FDA in late 2013 or early 2014 to initiate a NIH-funded human clinical study treating periodontitis with VSELTM.”
For more information about NeoStem, visit www.neostem.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
UV Flu Technologies, Inc. (UVFT) Kicks-Off Television Advertising Campaign
UV Flu Technologies, a developer, manufacturer, and distributor of biotechnology products, has launched a measure to build brand awareness and generate sales growth by retaining Stardust Broadcasting to run approximately 500 60-second television spots on a variety of national stations. The commercials are designed to educate consumers about the risks of indoor air pollution while promoting the UV Flu brand.
“These commercials are the beginning of a long-term program to drive sales, while informing viewers how they can protect their loved ones from the spread of airborne diseases, allergens, and virtually all other forms of indoor air pollution,” Jack Lennon, president of UV Flu stated in the press release.
The ads will start airing later this week on stations including CNN, ESPN, Fox News, Fox Sports, and the Discovery Channel.
This is the first phase of UV Flu’s plan to increase production and is the result of more than a year of planning.
“We are very excited about this first phase of our ramp-up. We have spent the last 18 months testing and evaluating the many applications for our products, and now we can focus on ramping up production to meet the demand we foresee from addressing the needs of each of these markets,” Lennon stated.
For more information, visit www.uvflutech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“These commercials are the beginning of a long-term program to drive sales, while informing viewers how they can protect their loved ones from the spread of airborne diseases, allergens, and virtually all other forms of indoor air pollution,” Jack Lennon, president of UV Flu stated in the press release.
The ads will start airing later this week on stations including CNN, ESPN, Fox News, Fox Sports, and the Discovery Channel.
This is the first phase of UV Flu’s plan to increase production and is the result of more than a year of planning.
“We are very excited about this first phase of our ramp-up. We have spent the last 18 months testing and evaluating the many applications for our products, and now we can focus on ramping up production to meet the demand we foresee from addressing the needs of each of these markets,” Lennon stated.
For more information, visit www.uvflutech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Soul and Vibe Interactive, Inc. (SOUL) Adds Micro-Transactions to Business Model for Console, Mobile, and PC Games
Soul and Vibe Interactive, a publisher of games and game-related content for consoles, mobile devices, and personal computers, told investors today of plans to include micro-transactions in its games across multiple platforms. Micro-transactions, or the purchase of additional functionality and/or content within a game, are growing ever more popular as gaming habits and purchase preferences advance.
Parks Associates published a research report showing how smartphones and tablets are changing the gaming population and the way players pay for games. Because many of today’s games are integrated with a player’s established online account for their hardware platform of choice, it is easier than ever for users to make in-game purchases. Notably, this report states that gamers who play “free-to-play” mobile games are spending $21 per month to purchase virtual goods and upgrades.
“Soul and Vibe’s publishing model is built on multi-platform support: console, mobile, and personal computer. Mobile games are key revenue generating marketing vehicles for our upcoming console and PC games. We will be supporting monetized content in all of our games, regardless of the platform, which allows us to expand the gaming experiences we introduce. Best yet, through support of cross-platform play, monetized content introduced through our mobile products will allow gamers to uniquely enhance their console and personal computer play experiences both at home and on the go,” stated Soul and Vibe’s CEO and President, Peter Anthony Chiodo (“Tony”).
The move is a smart one being made by other gaming companies. Electronic Arts, a $5.3 billion industry giant, also recently announced the inclusion of micro-transactions in its future games. Embraced by consumers, the micro-transaction model provides additional recurring revenue streams for the companies who employ it.
For more information, visit www.soulandvibe.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Parks Associates published a research report showing how smartphones and tablets are changing the gaming population and the way players pay for games. Because many of today’s games are integrated with a player’s established online account for their hardware platform of choice, it is easier than ever for users to make in-game purchases. Notably, this report states that gamers who play “free-to-play” mobile games are spending $21 per month to purchase virtual goods and upgrades.
“Soul and Vibe’s publishing model is built on multi-platform support: console, mobile, and personal computer. Mobile games are key revenue generating marketing vehicles for our upcoming console and PC games. We will be supporting monetized content in all of our games, regardless of the platform, which allows us to expand the gaming experiences we introduce. Best yet, through support of cross-platform play, monetized content introduced through our mobile products will allow gamers to uniquely enhance their console and personal computer play experiences both at home and on the go,” stated Soul and Vibe’s CEO and President, Peter Anthony Chiodo (“Tony”).
The move is a smart one being made by other gaming companies. Electronic Arts, a $5.3 billion industry giant, also recently announced the inclusion of micro-transactions in its future games. Embraced by consumers, the micro-transaction model provides additional recurring revenue streams for the companies who employ it.
For more information, visit www.soulandvibe.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Viscount Systems, Inc. (VSYS) Secures Midwestern Bank Facilities
Today before the opening bell, Viscount Systems announced that its Freedom access control technology is being installed at facilities owned by a regional bank with operations in Ohio, West Virginia, and Kentucky. Freedom IP bridges, Freedom servers, and software are all being employed, replacing the bank’s existing access control systems.
“This is the first deployment of Freedom into the financial services industry,” stated Stephen Pineau, President and CEO of Viscount. “While we are continuing to make great inroads within the U.S. Federal Government market, sales of Freedom to a wide range of other vertical markets, including banking, schools and multi-tenant high rises, are also increasing. It’s important to continue to diversify our end-user base among government and commercial customers.”
Utilizing existing logical IT security software (LDAP) to replace both the control panel component and the software component of traditional systems, Viscount’s Freedom technology eliminates up to 80% of the cost of traditional systems that require the installation of control panels. In addition to drastically reducing system costs, Freedom also provides a much more secure software solution.
For more information, visit www.viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“This is the first deployment of Freedom into the financial services industry,” stated Stephen Pineau, President and CEO of Viscount. “While we are continuing to make great inroads within the U.S. Federal Government market, sales of Freedom to a wide range of other vertical markets, including banking, schools and multi-tenant high rises, are also increasing. It’s important to continue to diversify our end-user base among government and commercial customers.”
Utilizing existing logical IT security software (LDAP) to replace both the control panel component and the software component of traditional systems, Viscount’s Freedom technology eliminates up to 80% of the cost of traditional systems that require the installation of control panels. In addition to drastically reducing system costs, Freedom also provides a much more secure software solution.
For more information, visit www.viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wave Systems Corp. (WAVX) Safend Data Protection Suite Selected by Doncaster and Bassetlaw NHS Foundation Trust
Wave Systems, the Trusted Computing Company, announced that the Safend Data Protection Suite (consisting of Safend Encryptor, Protector, and Reporter) has been chosen by Doncaster and Bassetlaw Hospitals NHS Foundation Trust as a replacement for existing technologies that perform data encryption, port device control, removable media encryption, and advanced monitoring.
The IT team from the Trust chose the Data Protection Suite specifically for transparent encryption, port control, and removable media encryption to protect data downloaded on USB sticks. Protector has the capability to provide traffic monitoring, as well as apply customized, highly granular security policies over all physical wireless and external devices. The Safend Reporter extends an additional layer of governance by enabling heightened visibility into what data was downloaded and when.
The Data Protection Suite has delivered increased security and convenience across the board, as well as provides transparency valued by users. IT also benefits from the increased protection, problem reduction, and the peace of mind of greater visibility. For example, Safend Encryptor aided in the standardization of the laptop experience, whether using a laptop inside one of the Trust hospitals or using one at home. IT was able to keep a cached copy of the staff’s H drives so they could work on the road with equivalent access, as if it were a local device.
Nigel Hall, ICT Infrastructure Manager of Doncaster and Bassetlaw Hospitals, said, “The Trust has a reputation for excellence in healthcare. We are here to implement an IT strategy that benefits the business function. The Safend technology has allowed our staff to use their devices with the confidence that they are secure. The IT department is now more centralised than before and that suits staff and patients alike.”
The awareness and training requirements of staff have been minimized since the introduction of Safend. For instance, while Safend Encryptor is transparent to the end user, it results in a negligible impact on performance because it bypasses unnecessary encryption of the operating system. The migration reinforces Doncaster and Bassetlaw Hospitals’ information governance message to its staff through Safend and Laptop user documentation. The nonstop communication in real time between the central server and remote assets guarantees that the entire contents of the laptop are consistently protected.
The Safend Data Protection Suite helps it comply with the Data Protection Act 1998, the Information Governance Toolkit, and the Department of Health’s mandate that all mobile data must be encrypted.
Joseph Souren, Vice President and GM Wave Systems EMEA commented, “Organisations in the public sector are becoming increasingly scrutinised for their IT practices and protection of data in particular. Safend Encryptor, Protector and Reporter are proven technologies and are able to provide the Trust functionality to help ensure the safety of patient and clinical data, as well as providing the workforce with a suitably flexible and secure means to work.”
For further information, visit www.wave.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The IT team from the Trust chose the Data Protection Suite specifically for transparent encryption, port control, and removable media encryption to protect data downloaded on USB sticks. Protector has the capability to provide traffic monitoring, as well as apply customized, highly granular security policies over all physical wireless and external devices. The Safend Reporter extends an additional layer of governance by enabling heightened visibility into what data was downloaded and when.
The Data Protection Suite has delivered increased security and convenience across the board, as well as provides transparency valued by users. IT also benefits from the increased protection, problem reduction, and the peace of mind of greater visibility. For example, Safend Encryptor aided in the standardization of the laptop experience, whether using a laptop inside one of the Trust hospitals or using one at home. IT was able to keep a cached copy of the staff’s H drives so they could work on the road with equivalent access, as if it were a local device.
Nigel Hall, ICT Infrastructure Manager of Doncaster and Bassetlaw Hospitals, said, “The Trust has a reputation for excellence in healthcare. We are here to implement an IT strategy that benefits the business function. The Safend technology has allowed our staff to use their devices with the confidence that they are secure. The IT department is now more centralised than before and that suits staff and patients alike.”
The awareness and training requirements of staff have been minimized since the introduction of Safend. For instance, while Safend Encryptor is transparent to the end user, it results in a negligible impact on performance because it bypasses unnecessary encryption of the operating system. The migration reinforces Doncaster and Bassetlaw Hospitals’ information governance message to its staff through Safend and Laptop user documentation. The nonstop communication in real time between the central server and remote assets guarantees that the entire contents of the laptop are consistently protected.
The Safend Data Protection Suite helps it comply with the Data Protection Act 1998, the Information Governance Toolkit, and the Department of Health’s mandate that all mobile data must be encrypted.
Joseph Souren, Vice President and GM Wave Systems EMEA commented, “Organisations in the public sector are becoming increasingly scrutinised for their IT practices and protection of data in particular. Safend Encryptor, Protector and Reporter are proven technologies and are able to provide the Trust functionality to help ensure the safety of patient and clinical data, as well as providing the workforce with a suitably flexible and secure means to work.”
For further information, visit www.wave.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Velti (VELT) Announces Launch of New Ad Network, Velti Media
Velti, a leading global provider of mobile marketing and advertising technology, announced the launch of a new mobile advertising network, Velti Media, which connects marketers to its 1.4 billion highly engaged consumers throughout the world. Velti is currently the only media company to combine mobile advertising and marketing solutions in a single technology platform across a unified data model, enabling the company to provide the most comprehensive suite of capabilities for brands to reach consumers on any device.
Velti is also unveiling its new technology, Multi-Channel Targeting (MCT), the first universal mobile analytics platform that allows brands to target consumers with relevant advertising and marketing interactions on smartphones, tablets, and PCs, allowing the company to more easily identify and reach the same consumers across any device or platform. Additionally, this allows advertisers to continue delivering deeper levels of engagement as consumers switch to other devices.
Velti is able to make recommendations to brands on the best types of campaigns to run in order to achieve a specific set of goals by combining advertising and marketing with performance data and predictive analysis. In the past, advertisers required the use of multiple solution providers in order to build their brand, drive conversion, and increase frequency and customer loyalty. However, with the advent of Velti’s technology, brands can now drive new consumers into the marketing funnel through advertising as well as make more money, increase engagement, and manage customer lifecycle management.
“As consumer device usage becomes increasingly fragmented, there is a growing urgency for all media and data to work together to deliver a consistent message to the consumer across all devices,” stated Alex Moukas, CEO of Velti. “Velti Media eliminates a major pain-point for marketers by giving them access to the consumer they want to target and providing them with the tools to reach them most effectively.”
Based in New York, Michael Hess leads the Velti Media sales team and joined the company in 2012 as SVP Advertising Sales, having previously held the position of SVP of Global Sales at Say Media. Hess also previously held positions at The New Yorker and Rolling Stone magazine.
For more information on Velti, visit www.velti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Velti is also unveiling its new technology, Multi-Channel Targeting (MCT), the first universal mobile analytics platform that allows brands to target consumers with relevant advertising and marketing interactions on smartphones, tablets, and PCs, allowing the company to more easily identify and reach the same consumers across any device or platform. Additionally, this allows advertisers to continue delivering deeper levels of engagement as consumers switch to other devices.
Velti is able to make recommendations to brands on the best types of campaigns to run in order to achieve a specific set of goals by combining advertising and marketing with performance data and predictive analysis. In the past, advertisers required the use of multiple solution providers in order to build their brand, drive conversion, and increase frequency and customer loyalty. However, with the advent of Velti’s technology, brands can now drive new consumers into the marketing funnel through advertising as well as make more money, increase engagement, and manage customer lifecycle management.
“As consumer device usage becomes increasingly fragmented, there is a growing urgency for all media and data to work together to deliver a consistent message to the consumer across all devices,” stated Alex Moukas, CEO of Velti. “Velti Media eliminates a major pain-point for marketers by giving them access to the consumer they want to target and providing them with the tools to reach them most effectively.”
Based in New York, Michael Hess leads the Velti Media sales team and joined the company in 2012 as SVP Advertising Sales, having previously held the position of SVP of Global Sales at Say Media. Hess also previously held positions at The New Yorker and Rolling Stone magazine.
For more information on Velti, visit www.velti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, March 27, 2013
Catalyst Pharmaceutical Partners, Inc. (CPRX) Receives Recommendation from Data Monitoring Committee Regarding Phase III Clinical Trial of Firdapse
Today, specialty pharmaceutical company Catalyst Pharmaceutical Partners announced that the independent data monitoring committee (DMC) overseeing its ongoing pivotal Phase III clinical trial of Firdapse recommended on March 25 that the company continue the trial as planned based on the committee’s review of safety and clinical data from the trial. Firdapse is currently being evaluated in the United States and Europe to treat Lambert-Easton Myasthenic Syndrome (LEMS).
The DMC is comprised of experts who are responsible for independently reviewing accumulated clinical safety and efficacy data obtained in Catalyst’s clinical trial, for the safety of participants and future patients. The committee considers data that is specific to the study, as well as pertinent background knowledge about the disease, test agent, or patient population being studied.
The Phase III clinical trial of Firdapse is designed as a randomized, double-blind, placebo-controlled discontinuation trial consisting of 30 enrolled patients who have been diagnosed with LEMS. The trial is taking place at sites within the U.S. and Europe. The company plans to add up to 20 more sites in the U.S., Europe, Canada, and South America and anticipates completing enrollment in the trial by the end of 2013’s fourth quarter. Catalyst plans to announce topline data from the trial during the second quarter of 2014.
Catalyst Pharmaceutical Partners is a specialty pharmaceutical company with its focus on developing and commercializing prescription drugs that target rare (orphan) neuromuscular and neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome, infantile spasms, and Tourette’s syndrome. Firdapse is the company’s lead candidate.
For more information, visit www.catalystpharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The DMC is comprised of experts who are responsible for independently reviewing accumulated clinical safety and efficacy data obtained in Catalyst’s clinical trial, for the safety of participants and future patients. The committee considers data that is specific to the study, as well as pertinent background knowledge about the disease, test agent, or patient population being studied.
The Phase III clinical trial of Firdapse is designed as a randomized, double-blind, placebo-controlled discontinuation trial consisting of 30 enrolled patients who have been diagnosed with LEMS. The trial is taking place at sites within the U.S. and Europe. The company plans to add up to 20 more sites in the U.S., Europe, Canada, and South America and anticipates completing enrollment in the trial by the end of 2013’s fourth quarter. Catalyst plans to announce topline data from the trial during the second quarter of 2014.
Catalyst Pharmaceutical Partners is a specialty pharmaceutical company with its focus on developing and commercializing prescription drugs that target rare (orphan) neuromuscular and neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome, infantile spasms, and Tourette’s syndrome. Firdapse is the company’s lead candidate.
For more information, visit www.catalystpharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Aristocrat Group Corp. (ASCC) Seeks Unique Approach in Billion-Dollar Flavored Vodka Market
In the past few years, an abundance of flavored vodkas have hit the market, from cotton candy to licorice and even bubble gum. In order to make a splash in the billion-dollar global flavored vodka market, though, the Aristocrat Group Corp. is targeting spirits tailored to the needs of mixologists, not drinkers.
“Most of the new vodka flavors you’ll find at the bar or liquor store are either sickeningly sweet or just plain gimmicky,” said ASCC CEO Robert Federowicz. “They’re meant to capitalize on a trend, not survive in a competitive marketplace. Our approach to flavored vodka will be different.”
With some analysts predicting that the flavored vodka segment will grow to $1.88 billion by 2016, ASCC sees tastefully flavored vodkas as a crucial element of its distilled spirits initiative. For the next in a line of vodka brands to be marketed by the company’s brand management division, Luxuria Brands, ASCC plans to concoct new flavored spirits intended for use behind the bar.
By infusing vodkas with the flavors of natural produce such as ginger, clove, orange peel, cocoa and more, the company plans to help mixologists create layered, flavorful cocktails that rely on fewer ingredients—and zero syrups and sugars.
“We’re exploring smokey, bitter and spicy notes to add to vodkas, not just sweeteners,” Federowicz said. “We want to put another tool into bartenders’ arsenal as they craft their next great cocktail, not just another flavor of the month that will be forgotten a year from now.”
Luxuria Brands is currently readying two separate vodka brands for hungry marketplace seen as key to successfully competing in a highly profitable sector alongside LVMH Moet Hennessy Louis Vuitton SA (EPA: MC), Diageo PLC (NYSE: DEO), BEAM Inc. (NYSE: BEAM) and Brown-Forman Corp. (NYSE: BF-B).
For more information on this initiative, please visit www.aristocratgroupcorp.com/investors.html.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“Most of the new vodka flavors you’ll find at the bar or liquor store are either sickeningly sweet or just plain gimmicky,” said ASCC CEO Robert Federowicz. “They’re meant to capitalize on a trend, not survive in a competitive marketplace. Our approach to flavored vodka will be different.”
With some analysts predicting that the flavored vodka segment will grow to $1.88 billion by 2016, ASCC sees tastefully flavored vodkas as a crucial element of its distilled spirits initiative. For the next in a line of vodka brands to be marketed by the company’s brand management division, Luxuria Brands, ASCC plans to concoct new flavored spirits intended for use behind the bar.
By infusing vodkas with the flavors of natural produce such as ginger, clove, orange peel, cocoa and more, the company plans to help mixologists create layered, flavorful cocktails that rely on fewer ingredients—and zero syrups and sugars.
“We’re exploring smokey, bitter and spicy notes to add to vodkas, not just sweeteners,” Federowicz said. “We want to put another tool into bartenders’ arsenal as they craft their next great cocktail, not just another flavor of the month that will be forgotten a year from now.”
Luxuria Brands is currently readying two separate vodka brands for hungry marketplace seen as key to successfully competing in a highly profitable sector alongside LVMH Moet Hennessy Louis Vuitton SA (EPA: MC), Diageo PLC (NYSE: DEO), BEAM Inc. (NYSE: BEAM) and Brown-Forman Corp. (NYSE: BF-B).
For more information on this initiative, please visit www.aristocratgroupcorp.com/investors.html.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
North Bay Resources Inc. (NBRI) Inks LOI to Run Material from Nearby Telegraph Mine Through Their Ruby Mill
North Bay Resources announced signing a LOI today with operator of the nearby Telegraph Mine, Lazarus Mining, LLC, to handle material from the mine using the excess capacity at the company’s Ruby Mine Mill complex, where the wash plant has ample throughput capacity (1k yards a day or around 1.5k tons of material).
A symbiotic relationship here is formed via the LOI which will be of mutual beneficial to both organizations. The Telegraph Mine is just outside nearby Downieville, which is the Sierra County seat, and because of the short travel distance of only a few miles to the Ruby Mill complex, the agreement gives NBRI some nice profitability metrics ahead of the Ruby Mill going into its own full production cycle.
The mill is standing virtually idle and Lazarus doesn’t have a wash plant. Telegraph is a comparable drift mine and the material is perfect for running through Ruby’s processing circuit. This is a no-brainer, especially given the proximity, which makes the logistics economically viable, and Lazarus is giving NBRI a sweetheart deal here with the greater of $10/ton, or 10% of the net sales, from the Telegraph material (plus expenses) in consideration.
Ruby is all set and ready to go, everything is in top shape and from NBRI’s standpoint this is better than a profitable processing contract, it’s a great low impact means of testing the mill’s throughput ahead of full production. The two companies are currently looking to slate a formal Toll Milling Agreement within the next 90 days and NBRI has intimated its eagerness to inform markets as soon as more news breaks on this front.
This is a smart play for NBRI ahead of the ramp up of production at their Ruby Mine, which is an underground placer and lode mine in the gorgeous Alleghany-Downieville mining district of California, just over the border to the west of Reno in the Sierra Nevada mountain range. Ruby is essentially on an extension of the historic Mother Lode system just west of the Yuba River and consists of subsurface mineral rights on 435 acres in 2 patented claims and another 1.32k acres in 30 unpatented claims. Ruby has very similar characteristics to the Telegraph placer drift mine and has around 135k oz of near-term recoverable Au according to the 2010 estimate. With operations set to commence in the middle of this year, some strong quartz gold potential in the geology and the mill capacity onsite to handle 50 tons/day of quartz, in addition to the aforementioned 1k yards/day wash plant, NBRI is chomping at the bit to run their own material.
CEO of NBRI, Perry Leopold, underscored the obvious synergies of the deal and reminded markets of the benefits of being a good neighbor in this industry. NBRI can pick up a nice chunk of change here and get the wash plant running material ahead of their own ramp up, while helping Lazarus (who would otherwise be stuck in the mud with no onsite processing capacity), allowing them to move forward instead of being stalled right out of the gate this season. Using similar material will allow NBRI to tune the plant for improved yields and will also give the company a chance to fix any kinks ahead of their own production schedule.
This LOI sets the company up nicely for their own season and helps build their reputation in the region as well. Word of such good business travels fast in the Sierra foothills even a century and a half after they pulled those jewelers-grade (as large as 201 ounce) nuggets out of the Ruby.
For more information on North Bay Resources, visit www.NorthBayResources.com
About QualityStocks
QualityStocksis committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
A symbiotic relationship here is formed via the LOI which will be of mutual beneficial to both organizations. The Telegraph Mine is just outside nearby Downieville, which is the Sierra County seat, and because of the short travel distance of only a few miles to the Ruby Mill complex, the agreement gives NBRI some nice profitability metrics ahead of the Ruby Mill going into its own full production cycle.
The mill is standing virtually idle and Lazarus doesn’t have a wash plant. Telegraph is a comparable drift mine and the material is perfect for running through Ruby’s processing circuit. This is a no-brainer, especially given the proximity, which makes the logistics economically viable, and Lazarus is giving NBRI a sweetheart deal here with the greater of $10/ton, or 10% of the net sales, from the Telegraph material (plus expenses) in consideration.
Ruby is all set and ready to go, everything is in top shape and from NBRI’s standpoint this is better than a profitable processing contract, it’s a great low impact means of testing the mill’s throughput ahead of full production. The two companies are currently looking to slate a formal Toll Milling Agreement within the next 90 days and NBRI has intimated its eagerness to inform markets as soon as more news breaks on this front.
This is a smart play for NBRI ahead of the ramp up of production at their Ruby Mine, which is an underground placer and lode mine in the gorgeous Alleghany-Downieville mining district of California, just over the border to the west of Reno in the Sierra Nevada mountain range. Ruby is essentially on an extension of the historic Mother Lode system just west of the Yuba River and consists of subsurface mineral rights on 435 acres in 2 patented claims and another 1.32k acres in 30 unpatented claims. Ruby has very similar characteristics to the Telegraph placer drift mine and has around 135k oz of near-term recoverable Au according to the 2010 estimate. With operations set to commence in the middle of this year, some strong quartz gold potential in the geology and the mill capacity onsite to handle 50 tons/day of quartz, in addition to the aforementioned 1k yards/day wash plant, NBRI is chomping at the bit to run their own material.
CEO of NBRI, Perry Leopold, underscored the obvious synergies of the deal and reminded markets of the benefits of being a good neighbor in this industry. NBRI can pick up a nice chunk of change here and get the wash plant running material ahead of their own ramp up, while helping Lazarus (who would otherwise be stuck in the mud with no onsite processing capacity), allowing them to move forward instead of being stalled right out of the gate this season. Using similar material will allow NBRI to tune the plant for improved yields and will also give the company a chance to fix any kinks ahead of their own production schedule.
This LOI sets the company up nicely for their own season and helps build their reputation in the region as well. Word of such good business travels fast in the Sierra foothills even a century and a half after they pulled those jewelers-grade (as large as 201 ounce) nuggets out of the Ruby.
For more information on North Bay Resources, visit www.NorthBayResources.com
About QualityStocks
QualityStocksis committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Seeking Alpha Publishes Article Featuring Advaxis, Inc. (ADXS)
Advaxis is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to fight off cancer and disease.
Earlier this week, Seeking Alpha published the following article featuring Advaxis: http://seekingalpha.com/article/1298241
The article titled “Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind” provides an overview of the pharmaceutical industry and its challenges. Strong competition from generic drug companies are pressuring Big Pharma to produce a new pipeline of drugs, either through research & development or acquisitions. Based on activity in the market as the pharmaceutical industry moves beyond the hollow specter of the patent cliff, there is a definite interest in buying up companies with promising efforts.
Jonathan Yates, author of the article, wrote, “Advaxis has more than 15 constructs in various stages of development that are not only distinct, but many are in strategic collaborations with such heavyweights as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institute, and others . . . Advaxis’ lead construct, ADXS-HPV, was honored as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards.”
While honors and awards light up a press release, investors only care about the glow from the bottom line. For the global market for immunotherapies from companies such as Advaxis and Dendreon, sales are estimated to be about $40 billion.
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Earlier this week, Seeking Alpha published the following article featuring Advaxis: http://seekingalpha.com/article/1298241
The article titled “Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind” provides an overview of the pharmaceutical industry and its challenges. Strong competition from generic drug companies are pressuring Big Pharma to produce a new pipeline of drugs, either through research & development or acquisitions. Based on activity in the market as the pharmaceutical industry moves beyond the hollow specter of the patent cliff, there is a definite interest in buying up companies with promising efforts.
Jonathan Yates, author of the article, wrote, “Advaxis has more than 15 constructs in various stages of development that are not only distinct, but many are in strategic collaborations with such heavyweights as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institute, and others . . . Advaxis’ lead construct, ADXS-HPV, was honored as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards.”
While honors and awards light up a press release, investors only care about the glow from the bottom line. For the global market for immunotherapies from companies such as Advaxis and Dendreon, sales are estimated to be about $40 billion.
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Viscount Systems Inc. (VSYS) Revolutionary Security Products
Viscount has been controlling facility access for over 30 years, but has today become a leader in the application of advanced IT technology to physical access. The foundation for this revolution is the company’s MESH Security Operating Platform, designed to reduce the complexity and cost of facility protection through the replacement of traditional hardware with IT servers and accessories. The result is more security for less money. The MESH platform is able to manage a large array of card access, intercom, video, and other devices, by using a common interface layer, and provides a critical and flexible foundation for Viscount products.
• Freedom – Viscount’s newest product, Freedom, is the world’s most advanced physical access control system. The system engages Microsoft’s Active Directory to offer unified logical and physical access control. It eliminates the need for costly dedicated access control panels, and removes cyber security risks associated with this legacy technology.
• Freedom Facility Friend – This is an add-on module to facilitate access control through manned entrances. Applications include photo badging, visitor management, incident reporting, scheduling, banned visitors, as well as lost-and-found. As a web-based application, it can link and manage an unlimited number of corporate locations.
• Freedom Cube – This is a software processing unit for the Freedom IP based system, with each Cube acting as a standalone access control system for up to 20 entrances. For more elaborate requirements, the Cubes can work as a local database appliance to provide redundant database support.
• Freedom Encryption Bridge – This is an IT platform that uses IP card reader bridges designed to eliminate the need of access control panels. You can turn any card reader into an IP device by connecting it to a Freedom Encryption Bridge.
• Freedom Raid Server – This is a premium central processing option. Each FRS can act as a standalone access control system, or can be used as a distributed database appliance working with other Freedom servers sharing data across a network.
• Freedom Mobile – This is Viscount’s latest software application. It eliminates the need for cards or readers by using a mobile device to open doors. It can also be used to track people or assets, plus can be used as an emergency notification system.
For additional information, visit www.Viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
• Freedom – Viscount’s newest product, Freedom, is the world’s most advanced physical access control system. The system engages Microsoft’s Active Directory to offer unified logical and physical access control. It eliminates the need for costly dedicated access control panels, and removes cyber security risks associated with this legacy technology.
• Freedom Facility Friend – This is an add-on module to facilitate access control through manned entrances. Applications include photo badging, visitor management, incident reporting, scheduling, banned visitors, as well as lost-and-found. As a web-based application, it can link and manage an unlimited number of corporate locations.
• Freedom Cube – This is a software processing unit for the Freedom IP based system, with each Cube acting as a standalone access control system for up to 20 entrances. For more elaborate requirements, the Cubes can work as a local database appliance to provide redundant database support.
• Freedom Encryption Bridge – This is an IT platform that uses IP card reader bridges designed to eliminate the need of access control panels. You can turn any card reader into an IP device by connecting it to a Freedom Encryption Bridge.
• Freedom Raid Server – This is a premium central processing option. Each FRS can act as a standalone access control system, or can be used as a distributed database appliance working with other Freedom servers sharing data across a network.
• Freedom Mobile – This is Viscount’s latest software application. It eliminates the need for cards or readers by using a mobile device to open doors. It can also be used to track people or assets, plus can be used as an emergency notification system.
For additional information, visit www.Viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VentriPoint Diagnostics Ltd. (VPTDF) Offers New Hope for CHD Patients
One of the challenges facing heart doctors is working with people having congenital heart disease (CHD). It’s a growing problem that involves unique issues. Though CHD is usually associated with children, a recent article by Michael O’Riordan in Clinical Cardiology (http://dtg.fm/5AjT) references a report indicating that the frequency of hospitalizations among adults for congenital defects has grown twice as fast as for children, with annual adult admissions now over a third of total CHD admissions. Among other factors, people who used to die young from such problems are now often living well into adulthood. The result is a growing burden on the healthcare system.
Accurate analysis of the heart can be a difficult and expensive process, and involves special issues dealing with the many children afflicted with the disease. Adding to the problem is the fact that people with CHD almost always have right heart defect, which can pose special challenges for accurate analysis. The unconventional shape, position, and size of the right ventricle has made it difficult to obtain reliable data regarding pump volume and cardiac function.
VentriPoint Diagnostics, a Canadian-based medical device company, offers what could be a breakthrough solution to the problems of accurate and comprehensive heart function analysis. The company’s new imaging system, called “Angelo,” is the only software available that offers comprehensive 3D imaging as quickly and cost-effectively, including the right heart. The system uses anatomical “dots” to build a 3D model of the heart, calculating such functional information as heart volumes, cardiac output, and ejection fraction, all within only 10 minutes, using conventional 2D ultrasound input.
The technology is based upon a patented approach known as knowledge-based reconstruction. The software can be added to any 2D ultrasound equipment, providing results that are faster, easier, and less expensive than any other heart assessment techniques. For both patients and doctors dealing with CHD, it offers new hope, and has already been approved for congenital heart disease application in Canada and Europe, with clinical trials currently finishing up in the U.S.
For more information, visit www.ventripoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Accurate analysis of the heart can be a difficult and expensive process, and involves special issues dealing with the many children afflicted with the disease. Adding to the problem is the fact that people with CHD almost always have right heart defect, which can pose special challenges for accurate analysis. The unconventional shape, position, and size of the right ventricle has made it difficult to obtain reliable data regarding pump volume and cardiac function.
VentriPoint Diagnostics, a Canadian-based medical device company, offers what could be a breakthrough solution to the problems of accurate and comprehensive heart function analysis. The company’s new imaging system, called “Angelo,” is the only software available that offers comprehensive 3D imaging as quickly and cost-effectively, including the right heart. The system uses anatomical “dots” to build a 3D model of the heart, calculating such functional information as heart volumes, cardiac output, and ejection fraction, all within only 10 minutes, using conventional 2D ultrasound input.
The technology is based upon a patented approach known as knowledge-based reconstruction. The software can be added to any 2D ultrasound equipment, providing results that are faster, easier, and less expensive than any other heart assessment techniques. For both patients and doctors dealing with CHD, it offers new hope, and has already been approved for congenital heart disease application in Canada and Europe, with clinical trials currently finishing up in the U.S.
For more information, visit www.ventripoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VistaGen Therapeutics, Inc. (VSTA) Uses Stem Cells to Build a Better Scientific Model for Drug Development
Why do pharmaceutical drugs cost so much? Because pharmaceutical companies waste so much money and time developing them.
But these companies can be excused for wasting hundreds of millions of dollars and years of work developing drugs that won’t be approved for use. The conventional method for initially testing the effectiveness and toxicity of these drugs – testing on animals – is terribly ineffective.
While scientific models like animals can provide a clue of how a drug might affect a human, they can never truly replicate the effects of giving the drug to people. Drugs that might not work in animal models – or even cause harmful effects – could produce an entirely different outcome when given to humans. But before government regulators will allow a drug to be tested on humans, it has to be proven safe in costly clinical trials with animal models or in vitro cell culture testing systems.
Drugs are scrapped every year by pharmaceutical companies after toxicity issues are discovered. The drugs are soon forgotten as the companies move on to find the next “wonder drug.” If scientists had a more accurate scientific model to perform initial tests on, they would be able to better predict which drugs are safe and which aren’t long before large investments are made.
A San Francisco-based biotechnology company, VistaGen Therapeutics, is focused on changing all of this through its novel platform Human Clinical Trials in a Test Tube™. The platform uses proprietary and exclusively-licensed stem cell technologies, some co-developed by Dr. Gordon Keller, a world renowned stem cell scientist.
In addition to providing toxicity predations for new drugs, the platform is designed to “rescue” once-promising small molecule drug candidates that were shelved because they exhibited negative effects in studies using conventional scientific models. Development of these drug candidates are often halted due to signs of heart or liver toxicity or metabolism issues during tests using scientific models like animals or in vitro cell culture testing systems.
The Human Clinical Trials in a Test Tube platform enables controlled differentiation of pluripotent stem cells into mature human cells, which are a more accurate model for clinical trials. The platform helps scientists determine if the negative effects experienced in previous trials with conventional models apply to humans. It can also be used to help generate new, safer variants in combination with modern medicinal chemistry.
By developing scientific models which more closely approximate human biology, VistaGen is helping pharmaceutical companies more accurately assess how new drug therapies will perform in clinical trials. The Human Clinical Trials in a Test Tube platform also provides useful clinical data earlier in the drug development process – so drug companies will know sooner which drugs might work … and which drugs won’t. Having this information much sooner in the development cycle will help increase the efficiency of clinical trials and eliminate the waste of valuable resources.
For more information, visit VistaGen at www.VistaGen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
But these companies can be excused for wasting hundreds of millions of dollars and years of work developing drugs that won’t be approved for use. The conventional method for initially testing the effectiveness and toxicity of these drugs – testing on animals – is terribly ineffective.
While scientific models like animals can provide a clue of how a drug might affect a human, they can never truly replicate the effects of giving the drug to people. Drugs that might not work in animal models – or even cause harmful effects – could produce an entirely different outcome when given to humans. But before government regulators will allow a drug to be tested on humans, it has to be proven safe in costly clinical trials with animal models or in vitro cell culture testing systems.
Drugs are scrapped every year by pharmaceutical companies after toxicity issues are discovered. The drugs are soon forgotten as the companies move on to find the next “wonder drug.” If scientists had a more accurate scientific model to perform initial tests on, they would be able to better predict which drugs are safe and which aren’t long before large investments are made.
A San Francisco-based biotechnology company, VistaGen Therapeutics, is focused on changing all of this through its novel platform Human Clinical Trials in a Test Tube™. The platform uses proprietary and exclusively-licensed stem cell technologies, some co-developed by Dr. Gordon Keller, a world renowned stem cell scientist.
In addition to providing toxicity predations for new drugs, the platform is designed to “rescue” once-promising small molecule drug candidates that were shelved because they exhibited negative effects in studies using conventional scientific models. Development of these drug candidates are often halted due to signs of heart or liver toxicity or metabolism issues during tests using scientific models like animals or in vitro cell culture testing systems.
The Human Clinical Trials in a Test Tube platform enables controlled differentiation of pluripotent stem cells into mature human cells, which are a more accurate model for clinical trials. The platform helps scientists determine if the negative effects experienced in previous trials with conventional models apply to humans. It can also be used to help generate new, safer variants in combination with modern medicinal chemistry.
By developing scientific models which more closely approximate human biology, VistaGen is helping pharmaceutical companies more accurately assess how new drug therapies will perform in clinical trials. The Human Clinical Trials in a Test Tube platform also provides useful clinical data earlier in the drug development process – so drug companies will know sooner which drugs might work … and which drugs won’t. Having this information much sooner in the development cycle will help increase the efficiency of clinical trials and eliminate the waste of valuable resources.
For more information, visit VistaGen at www.VistaGen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Local Corp. (LOCM) Launches Premium Ad Network
Leading local online media company, Local Corp. announced that it has launched “Fusion by Local,” a new premium ad network for advertisers and brand marketers. Fusion by Local helps advertisers reach targeted customers in local markets through premium display advertising inventory across some of the top media properties in the country, including in the company’s established network of over 1,000 regional media sites.
Local Corporation’s new platform has launched at a promising time¬. With local display advertising on the rise and expected to grow 18.2 percent this year, advertisers are seeking ways to more effectively engage target audiences on a local level. National and regional brands are also seeking premium ad positioning for their campaigns near relevant content, with high quality publishers and media sites. Fusion by Local offers both by combining its precision-based audience targeting with premium advertising inventory that takes the manual process out of local buying.
Fusion by Local also eliminates the process of contacting publishers, negotiating multiple contracts, submitting insertion orders, and tracking performance metrics for each media property. The platform offers a variety of standard and customized ad units across various ad formats, including mobile and rich media, through a single integrated process with one point of contact.
Lori Chavez, Local Corporation’s VP-Marketing, remarked, “Implementing local campaigns is a labor-intensive process that involves manually engaging with hundreds of media sites across the U.S. Fusion by Local removes this burden from advertisers by allowing them to leverage our existing relationships with these valuable regional media publishers so they can focus their time on campaign strategy not campaign implementation. Fusion by Local further expands our local ecosystem and directly supports our mission of connecting local consumers with businesses of all sizes online.”
For more information, visit www.local.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Local Corporation’s new platform has launched at a promising time¬. With local display advertising on the rise and expected to grow 18.2 percent this year, advertisers are seeking ways to more effectively engage target audiences on a local level. National and regional brands are also seeking premium ad positioning for their campaigns near relevant content, with high quality publishers and media sites. Fusion by Local offers both by combining its precision-based audience targeting with premium advertising inventory that takes the manual process out of local buying.
Fusion by Local also eliminates the process of contacting publishers, negotiating multiple contracts, submitting insertion orders, and tracking performance metrics for each media property. The platform offers a variety of standard and customized ad units across various ad formats, including mobile and rich media, through a single integrated process with one point of contact.
Lori Chavez, Local Corporation’s VP-Marketing, remarked, “Implementing local campaigns is a labor-intensive process that involves manually engaging with hundreds of media sites across the U.S. Fusion by Local removes this burden from advertisers by allowing them to leverage our existing relationships with these valuable regional media publishers so they can focus their time on campaign strategy not campaign implementation. Fusion by Local further expands our local ecosystem and directly supports our mission of connecting local consumers with businesses of all sizes online.”
For more information, visit www.local.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
International Stem Cell Corp. (ISCO) Reports 2012 Financial Results and Updates Investors
International Stem Cell Corp., a biotechnology company focused on therapeutic and biomedical products using human parthenogenetic stem cells (hpSCs), announced its financial results for the three and twelve months ended December 31, 2012.
FY 2012 Highlights:
• Made significant progress in Parkinson’s program including the development of a new highly-efficient manufacturing method for generating neuronal cells and conducted preliminary toxicology and pharmacology studies in animals.
• Added world-recognized neurobiologist, Dr. Evan Y. Snyder, head of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, Director of the Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute, as an non-compensated member of our Board of Advisors.
• Expanded stem cell bank to a total of fifteen human lines by adding three new cGMP-grade stem cell lines, derived in the ISCO’s California facility, capable of immune-matching millions of individuals.
• Developed a new protein-based technology to derive iPS cells without the use of viruses as in traditional methods.
• Received a key patent issued by the USPTO covering the creation of liver and pancreas precursor cells. Performed hybrid toxicology/pharmacology study in a rodent model of Crigler-Najjar disease.
• Progressed the Cornea program by the development of endothelial-like cells for 3D corneal structures as part of our Indian collaboration.
• Realized 14% increase in sales in Lifeline Cell Technologies to $2.38 million for 2012.
• Significantly expanded marketing activities, brand awareness, diversified sales channels and launched new eye firming serum in Lifeline Skin Care, all of which lead to higher sales in second half of the year.
• Raised $7.03 million and reduced G&A expenses by 11% compared with 2011.
Fourth quarter revenue was reported at $1.25 million compared to $1.06 million for the same period in 2011. Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 39% and 3%, respectively. According to today’s press release, LSC and LCT accounted for 48% and 52% of total revenue in the three months ended December 31, 2012.
Development expenses were down by 8% to $3.65 million. The company attributed the decrease to reductions in cost of sales and consulting expenses relating to its research and development projects, partially offset by an increase in sales and marketing spending. General and administrative expenses totaled $1.89 million, reflecting relatively constant expense compared to the prior year.
Sales for the entire year of 2012 were $4.57 million compared to $4.53 million in 2011. LCT sales totaled $2.38 million, up 14% from 2011, representing a little over half of total revenue in 2012. LSC revenues were $2.19 million compared to $2.45 million in 2011.
Cost of sales totaled $1.27 million, or 28% of revenue, compared to $1.62 million, or 36% of revenue, a year earlier. The company added efficiencies to its manufacturing and supply chain management for both LSC and LCT.
Net loss from development activities was $9.81 million, compared to $11.36 million in 2011, a 14% reduction primarily due to favorable reductions in cost of sales, research and development expenses, and general and administrative costs.
“We have made excellent progress in our therapeutic development programs, being able to start our non-human primate study in our Parkinson’s disease program earlier than anticipated, and report top line data at the American Academy of Neurology Annual Meeting,” commented Dr. Andrey Semechkin, ISCO’s CEO and Co-Chairman. “In addition, our results for the fourth quarter reflect good progress by LSC and LCT both in terms of growing sales and implementing their strategies. Particularly pleasing is LSC’s continued quarterly revenue growth as they aim to diversify their sales channels, and LCT’s strong annual results. General and administrative expenses continued to decrease reflecting our increased focus on cost containment. Looking ahead to the next twelve months, we anticipate our R&D expenses to increase as we expand our pharmacology and safety studies and our Parkinson’s program moves closer to our targeted IND filing in early 2014.”
Conference Call and Webcast Details
Date: Thursday, March 28, 2013
Time: 11:00 a.m. Eastern Time
Conference Call Dial-in Numbers
Participants from US Domestic: 1-877-941-2068
Participants from International: 1-480-629-9712
Conference ID: 4610666
Webcast link: http://public.viavid.com/player/index.php?id=104040
The company encourages participants to log into the call 10 minutes prior to the start time.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
FY 2012 Highlights:
• Made significant progress in Parkinson’s program including the development of a new highly-efficient manufacturing method for generating neuronal cells and conducted preliminary toxicology and pharmacology studies in animals.
• Added world-recognized neurobiologist, Dr. Evan Y. Snyder, head of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, Director of the Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute, as an non-compensated member of our Board of Advisors.
• Expanded stem cell bank to a total of fifteen human lines by adding three new cGMP-grade stem cell lines, derived in the ISCO’s California facility, capable of immune-matching millions of individuals.
• Developed a new protein-based technology to derive iPS cells without the use of viruses as in traditional methods.
• Received a key patent issued by the USPTO covering the creation of liver and pancreas precursor cells. Performed hybrid toxicology/pharmacology study in a rodent model of Crigler-Najjar disease.
• Progressed the Cornea program by the development of endothelial-like cells for 3D corneal structures as part of our Indian collaboration.
• Realized 14% increase in sales in Lifeline Cell Technologies to $2.38 million for 2012.
• Significantly expanded marketing activities, brand awareness, diversified sales channels and launched new eye firming serum in Lifeline Skin Care, all of which lead to higher sales in second half of the year.
• Raised $7.03 million and reduced G&A expenses by 11% compared with 2011.
Fourth quarter revenue was reported at $1.25 million compared to $1.06 million for the same period in 2011. Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 39% and 3%, respectively. According to today’s press release, LSC and LCT accounted for 48% and 52% of total revenue in the three months ended December 31, 2012.
Development expenses were down by 8% to $3.65 million. The company attributed the decrease to reductions in cost of sales and consulting expenses relating to its research and development projects, partially offset by an increase in sales and marketing spending. General and administrative expenses totaled $1.89 million, reflecting relatively constant expense compared to the prior year.
Sales for the entire year of 2012 were $4.57 million compared to $4.53 million in 2011. LCT sales totaled $2.38 million, up 14% from 2011, representing a little over half of total revenue in 2012. LSC revenues were $2.19 million compared to $2.45 million in 2011.
Cost of sales totaled $1.27 million, or 28% of revenue, compared to $1.62 million, or 36% of revenue, a year earlier. The company added efficiencies to its manufacturing and supply chain management for both LSC and LCT.
Net loss from development activities was $9.81 million, compared to $11.36 million in 2011, a 14% reduction primarily due to favorable reductions in cost of sales, research and development expenses, and general and administrative costs.
“We have made excellent progress in our therapeutic development programs, being able to start our non-human primate study in our Parkinson’s disease program earlier than anticipated, and report top line data at the American Academy of Neurology Annual Meeting,” commented Dr. Andrey Semechkin, ISCO’s CEO and Co-Chairman. “In addition, our results for the fourth quarter reflect good progress by LSC and LCT both in terms of growing sales and implementing their strategies. Particularly pleasing is LSC’s continued quarterly revenue growth as they aim to diversify their sales channels, and LCT’s strong annual results. General and administrative expenses continued to decrease reflecting our increased focus on cost containment. Looking ahead to the next twelve months, we anticipate our R&D expenses to increase as we expand our pharmacology and safety studies and our Parkinson’s program moves closer to our targeted IND filing in early 2014.”
Conference Call and Webcast Details
Date: Thursday, March 28, 2013
Time: 11:00 a.m. Eastern Time
Conference Call Dial-in Numbers
Participants from US Domestic: 1-877-941-2068
Participants from International: 1-480-629-9712
Conference ID: 4610666
Webcast link: http://public.viavid.com/player/index.php?id=104040
The company encourages participants to log into the call 10 minutes prior to the start time.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
OxySure Systems, Inc. (OXYS) Taps into Diverse Expertise of New Independent Director Jerry Jones
OxySure® Systems, a medical device innovator of emergency oxygen solutions, has named Jeremy M. (“Jerry”) Jones, former chairman and CEO of Apria Healthcare, as an independent director effective April 1, 2013.
During his more than 35 years of experience in the healthcare industry, Jones has led healthcare industry coalition efforts; served two terms as chairman of the Health Industry Distributors Association (HIDA); was a board member of the National Association of Medical Equipment Services; and was founding chairman of the Home Oxygen Services Coalition. He received the Dr. Jonas Salk Memorial Mentor in Medicine Award from the March of Dimes, in recognition of his medical achievements and support of wellness programs aimed at the prevention of birth defects.
Jones’ prior experience also includes his founding of Homedco Group, Inc., a home healthcare services company he took public in 1991. Four years later, Jones led Homedco’s merger into Apria Healthcare Group, Inc., which became the largest homecare service provider. Jones served the company as CEO and chairman from 1995 through 1998 when the company was sold to the Blackstone Group for $1.7 billion.
“We are pleased to welcome Jerry to our board,” Julian Ross, CEO of OxySure stated in the press release. “As we pursue our goal of providing OxySure as a standard safety item for all homes and businesses worldwide, I am convinced that Jerry’s expansive medical and healthcare sector experience and product distribution knowledge, combined with his extensive network of industry associates will be invaluable to our company.”
Jones also currently serves as chairman of On Assignment, Inc. (ASGN), a $1.3 billion healthcare and life sciences company focused on medical and technical staffing, and is a member of the board of CombiMatrix Corp. (CBMX).
For more information, visit www.OxySure.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
During his more than 35 years of experience in the healthcare industry, Jones has led healthcare industry coalition efforts; served two terms as chairman of the Health Industry Distributors Association (HIDA); was a board member of the National Association of Medical Equipment Services; and was founding chairman of the Home Oxygen Services Coalition. He received the Dr. Jonas Salk Memorial Mentor in Medicine Award from the March of Dimes, in recognition of his medical achievements and support of wellness programs aimed at the prevention of birth defects.
Jones’ prior experience also includes his founding of Homedco Group, Inc., a home healthcare services company he took public in 1991. Four years later, Jones led Homedco’s merger into Apria Healthcare Group, Inc., which became the largest homecare service provider. Jones served the company as CEO and chairman from 1995 through 1998 when the company was sold to the Blackstone Group for $1.7 billion.
“We are pleased to welcome Jerry to our board,” Julian Ross, CEO of OxySure stated in the press release. “As we pursue our goal of providing OxySure as a standard safety item for all homes and businesses worldwide, I am convinced that Jerry’s expansive medical and healthcare sector experience and product distribution knowledge, combined with his extensive network of industry associates will be invaluable to our company.”
Jones also currently serves as chairman of On Assignment, Inc. (ASGN), a $1.3 billion healthcare and life sciences company focused on medical and technical staffing, and is a member of the board of CombiMatrix Corp. (CBMX).
For more information, visit www.OxySure.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
UQM Technologies, Inc. (UQM) Powers Audi Test Expansion
UQM Technologies announced that the company will be providing the systems that Audi will be testing in its A1 e-tron extended range electric vehicles. UQM’s PowerPhase systems will be used in testing that will occur through 2013 in Germany’s National Platform of Electrification; the NPE is promoting this program to demonstrate and further develop the viability of electric vehicles.
Longmont, CO-based UQM is focused on developing and manufacturing power-dense, high-efficiency electric motors, generators and power electronic controllers for the automotive, commercial truck, bus, marine, and military markets. In addition, UQM is developing propulsion systems for electric, hybrid electric, plug-in hybrid electric, and fuel cell electric vehicles.
Extended-range vehicles rely on the electric powertrain for propulsion and use an internal combustion engine to charge the battery pack. For example, the Audi A1 e-tron extended-range all-electric test-fleet vehicles use UQM PowerPhase Select 125 systems to drive the wheels at all times. The combustion engine in the car is used to generate electricity to extend the range as needed. The maximum all-electric range of the A1 e-tron is 30 miles (50 km), while the maximum combined range in the New European Driving Cycle is 155 miles (250 km).
Eric R. Ridenour, President and CEO of UQM, said, “The key attributes of our electric motors and controllers offer the same advantages in extended-range electric vehicles as they do in electric-only applications. Our higher efficiency systems provide the potential for longer all-electric mode and an overall improved fuel economy in extended-range vehicles.”
For more information, visit www.uqm.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Longmont, CO-based UQM is focused on developing and manufacturing power-dense, high-efficiency electric motors, generators and power electronic controllers for the automotive, commercial truck, bus, marine, and military markets. In addition, UQM is developing propulsion systems for electric, hybrid electric, plug-in hybrid electric, and fuel cell electric vehicles.
Extended-range vehicles rely on the electric powertrain for propulsion and use an internal combustion engine to charge the battery pack. For example, the Audi A1 e-tron extended-range all-electric test-fleet vehicles use UQM PowerPhase Select 125 systems to drive the wheels at all times. The combustion engine in the car is used to generate electricity to extend the range as needed. The maximum all-electric range of the A1 e-tron is 30 miles (50 km), while the maximum combined range in the New European Driving Cycle is 155 miles (250 km).
Eric R. Ridenour, President and CEO of UQM, said, “The key attributes of our electric motors and controllers offer the same advantages in extended-range electric vehicles as they do in electric-only applications. Our higher efficiency systems provide the potential for longer all-electric mode and an overall improved fuel economy in extended-range vehicles.”
For more information, visit www.uqm.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Liquidmetal Technologies Inc. (LQMT) Video Chart for Wednesday, March 27, 2013
LQMT has found support levels at 7.6 cents and 8 cents. In the past month the chart has made two higher highs and climbed back over the 50-day simple moving average, putting it on technical watch to potentially test the highs at 11.4 cents again.
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, March 26, 2013
Soul and Vibe Interactive, Inc. (SOUL) Parallels Movie Industry with Creative Monetization
When the motion picture industry was still young, revenue was based upon one source, the money paid by the movie goer to see a movie. As the industry developed, however, companies like Disney began to realize the income potential from character development and corresponding licensing. Disney currently pulls in close to $30 billion in licensed merchandise fees, far more than it does from movie sales or other sources, and is considered the world’s top licensor. Today, the same type of ancillary monetization is being applied in the video gaming industry, though in somewhat different ways.
Soul and Vibe Interactive, a publisher of games and games-related content for consoles, mobile devices, and personal computers, specializing in the creation of original intellectual properties, is a good example. The company’s business model calls for numerous revenue streams to be generated from each game release, and the Minnesota-based company is continuing to develop revenue streams separate from the purchase of games. In particular, each game product will be supported by a recurring release of monetized games-related content. Ancillary revenue is to be generated from the sale of Premium Downloadable Content (“PDLC”), virtual apparel and costumes for Avatars, and monetized “Consumables.” Their mobile games are also designed to be revenue generating marketing vehicles for their console releases.
In addition, the company’s digitally-oriented distribution and marketing model provides additional licensing control. “IP” ownership allows Soul to control the licensing of their properties to 3rd Party merchandising companies, and to retain the majority of revenues, maximizing shareholder value. The video and computer games industry has historically distributed and marketed physical media through traditional retail channels. The digital distribution and marketing of content is relatively new, but Soul was founded with a business model that fully embraces digital distribution. It’s an approach that can be focused on the end consumer, avoiding the challenges and costs associated with physical media distribution.
For additional information, visit www.SoulAndVibe.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Soul and Vibe Interactive, a publisher of games and games-related content for consoles, mobile devices, and personal computers, specializing in the creation of original intellectual properties, is a good example. The company’s business model calls for numerous revenue streams to be generated from each game release, and the Minnesota-based company is continuing to develop revenue streams separate from the purchase of games. In particular, each game product will be supported by a recurring release of monetized games-related content. Ancillary revenue is to be generated from the sale of Premium Downloadable Content (“PDLC”), virtual apparel and costumes for Avatars, and monetized “Consumables.” Their mobile games are also designed to be revenue generating marketing vehicles for their console releases.
In addition, the company’s digitally-oriented distribution and marketing model provides additional licensing control. “IP” ownership allows Soul to control the licensing of their properties to 3rd Party merchandising companies, and to retain the majority of revenues, maximizing shareholder value. The video and computer games industry has historically distributed and marketed physical media through traditional retail channels. The digital distribution and marketing of content is relatively new, but Soul was founded with a business model that fully embraces digital distribution. It’s an approach that can be focused on the end consumer, avoiding the challenges and costs associated with physical media distribution.
For additional information, visit www.SoulAndVibe.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Americas Diamond Corp. (ADMC) Kicks Off Crucial Site Prep Work at Venezuelan Diamond Digs Ahead of Upcoming Bulk Sampling Program
Americas Diamond Corp. reported starting up essential site prep work today at their Natal I and II concessions, well ahead of the final bulk sampling program aimed at running some 100k tonnes of good material through the diamond recovery plant.
Looking at the extant sampling and recovery rates from the project thus far, ADMC is calculating double or even quadruple (10k to 20k carats total) the generally accepted as required return needed to successfully characterize the material’s diamond population. With moisture receding from what was described by the company as a very heavy rain season (over 300 inches in just nine months or so), the project is springing to life again now with earth movers hammering out roadway refurbishments and crews doing upkeep on several key onsite bridges, bringing overall logistical accessibility up to where it needs to be for the coming work.
The company’s wholly-owned Venezuelan subsidiary, Compania Minera Adamantine C.A., holds these two sizeable (15.7k acres combined) diamond concessions, which have seen over $13M total investment to date. Though limited to small-scale, semi-mechanized, and artisan mining, the host Guaniamo Diamond Province’s rich kimberlite has pumped out well over 15M carats since its discovery in 1969 (estimates are nearly double that official figure, including some 60-carat whoppers). ADMC acreage is in the heart of the prolific region and analysts expect big things out of Natal I and II.
CEO of ADMC, Daniel Martinez, spoke of the crucial nature of this preparatory work for ensuring that the $1M to $2M (plus another $250k or so for year one CAPEX) budgeted for the sampling program was well spent. Given the potential of the down-dip extensions in the Belmudez diamondiferous zone, the probing of which is an overarching goal for the program, it is essential to make sure the logistics are tight before kicking off. In addition to roads and bridges on the site’s interior, ADMC is hard at work shoring up external access, like the Chalana ferry terminal road that links to the camp and plant.
New roadways are being put in to service the Belmudez zone targets in anticipation of their evolution and all the necessary machines, vehicles, and equipment are getting the once-over. Preemptive repairs and routine maintenance like this will ensure that critical uptime is not lost during the sampling program, as such downtime impairs cost efficiency and could jeopardize the program’s true potential. ADMC is moving to get spare parts for the plant as well, in shrewd anticipation of the inevitable, ordering up the necessary screens, spigots, and pumps for the DMS 3-Stage unit.
Another thing they are looking to grab early on in the work season here is dedicated automotive spares to support the earthmovers tasked with doing the long extension inclines, as this job is particularly wear-and-tear intensive. This is the kind of thing you want to see as an investor, smart site prep in anticipation of the digging season. You can tell straight away that ADMC is serious about knocking it out of the park with their main bulk diamond sampling program, just by the way they are hitting the ground running here.
With permits in hand to acquire and stockpile thousands of gallons of low-cost petrol/diesel for the dig, ADMC is itching to get at those down-dip extensions and start running material.
For more information on Americas Diamond, visit www.AmericasDiamondCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Looking at the extant sampling and recovery rates from the project thus far, ADMC is calculating double or even quadruple (10k to 20k carats total) the generally accepted as required return needed to successfully characterize the material’s diamond population. With moisture receding from what was described by the company as a very heavy rain season (over 300 inches in just nine months or so), the project is springing to life again now with earth movers hammering out roadway refurbishments and crews doing upkeep on several key onsite bridges, bringing overall logistical accessibility up to where it needs to be for the coming work.
The company’s wholly-owned Venezuelan subsidiary, Compania Minera Adamantine C.A., holds these two sizeable (15.7k acres combined) diamond concessions, which have seen over $13M total investment to date. Though limited to small-scale, semi-mechanized, and artisan mining, the host Guaniamo Diamond Province’s rich kimberlite has pumped out well over 15M carats since its discovery in 1969 (estimates are nearly double that official figure, including some 60-carat whoppers). ADMC acreage is in the heart of the prolific region and analysts expect big things out of Natal I and II.
CEO of ADMC, Daniel Martinez, spoke of the crucial nature of this preparatory work for ensuring that the $1M to $2M (plus another $250k or so for year one CAPEX) budgeted for the sampling program was well spent. Given the potential of the down-dip extensions in the Belmudez diamondiferous zone, the probing of which is an overarching goal for the program, it is essential to make sure the logistics are tight before kicking off. In addition to roads and bridges on the site’s interior, ADMC is hard at work shoring up external access, like the Chalana ferry terminal road that links to the camp and plant.
New roadways are being put in to service the Belmudez zone targets in anticipation of their evolution and all the necessary machines, vehicles, and equipment are getting the once-over. Preemptive repairs and routine maintenance like this will ensure that critical uptime is not lost during the sampling program, as such downtime impairs cost efficiency and could jeopardize the program’s true potential. ADMC is moving to get spare parts for the plant as well, in shrewd anticipation of the inevitable, ordering up the necessary screens, spigots, and pumps for the DMS 3-Stage unit.
Another thing they are looking to grab early on in the work season here is dedicated automotive spares to support the earthmovers tasked with doing the long extension inclines, as this job is particularly wear-and-tear intensive. This is the kind of thing you want to see as an investor, smart site prep in anticipation of the digging season. You can tell straight away that ADMC is serious about knocking it out of the park with their main bulk diamond sampling program, just by the way they are hitting the ground running here.
With permits in hand to acquire and stockpile thousands of gallons of low-cost petrol/diesel for the dig, ADMC is itching to get at those down-dip extensions and start running material.
For more information on Americas Diamond, visit www.AmericasDiamondCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
SEC Ponders Tick-Size Pilot Program; Advocates and Critics Weigh In
The Securities and Exchange Commission (SEC) is mulling a pilot program to test determine whether larger trading increments would trigger more active trading in the small-cap market and result in subsidized analyst research on small stocks.
The theory is that wider tick sizes would expand the spread between bid and offer prices and drive higher profits for market makers who, ideally, would subsidize research and draft revived interest in small stocks.
Supporters of the program say wider minimum tick sizes will spur an increase in the number of small companies going public, while cynics contend the program will cause people to shell out more money when they trade with slim to no benefit to the companies.
Regardless, the answer may be a long time coming. Experts say that even a well-designed pilot program would take at least five years to generate relevant data that could provide an accurate verdict.
OTC Markets Group CEO R. Cromwell Coulson told Bloomberg that the pilot program should require market makers to indicate minimum quote size to safeguard the depth and liquidity of the market, which he believes would increase investors’ inclination to trade.
Some believe higher tick sizes will revive capital formation, generate jobs by supporting small public companies, and boost investor confidence to grow the small IPO market, which they say was roiled by decimalization, the rule implemented in 2001 to replace fractions in stock prices with penny increments.
Dissenters argue that narrowed tick sizes encourage securities firms to buy and sell more shares by making it more profitable for them to do so.
Another consideration is whether or not each company should be able to choose its own tick size, while skeptics point out that the benefits, if any, of varying tick sizes are unknown.
SEC spokeswoman Judith Burns declined to say when the program might be approved, though the program would likely be launched under the SEC’s next chairman, who at this point may be Mary Jo White, President Barack Obama’s nominee as the agency’s next chairman.
Earlier this month at her nomination hearing before the Senate Banking Committee, White told senators that she that one tick size “doesn’t necessarily fit all,” but that “Clearly, it’s a priority to focus on that issue.”
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The theory is that wider tick sizes would expand the spread between bid and offer prices and drive higher profits for market makers who, ideally, would subsidize research and draft revived interest in small stocks.
Supporters of the program say wider minimum tick sizes will spur an increase in the number of small companies going public, while cynics contend the program will cause people to shell out more money when they trade with slim to no benefit to the companies.
Regardless, the answer may be a long time coming. Experts say that even a well-designed pilot program would take at least five years to generate relevant data that could provide an accurate verdict.
OTC Markets Group CEO R. Cromwell Coulson told Bloomberg that the pilot program should require market makers to indicate minimum quote size to safeguard the depth and liquidity of the market, which he believes would increase investors’ inclination to trade.
Some believe higher tick sizes will revive capital formation, generate jobs by supporting small public companies, and boost investor confidence to grow the small IPO market, which they say was roiled by decimalization, the rule implemented in 2001 to replace fractions in stock prices with penny increments.
Dissenters argue that narrowed tick sizes encourage securities firms to buy and sell more shares by making it more profitable for them to do so.
Another consideration is whether or not each company should be able to choose its own tick size, while skeptics point out that the benefits, if any, of varying tick sizes are unknown.
SEC spokeswoman Judith Burns declined to say when the program might be approved, though the program would likely be launched under the SEC’s next chairman, who at this point may be Mary Jo White, President Barack Obama’s nominee as the agency’s next chairman.
Earlier this month at her nomination hearing before the Senate Banking Committee, White told senators that she that one tick size “doesn’t necessarily fit all,” but that “Clearly, it’s a priority to focus on that issue.”
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Publication of Nutra Pharma Corp.’s (NPHC) Patented Nyloxin™ Treatment Increases International Distribution Opportunity
Nutra Pharma Corp., a biotechnology company focused on the development of treatments for neurological disorders, cancer, autoimmune, infectious diseases, and pain, said that its patent and trademarks for the company’s Nyloxin™ line of pain relievers have been published in India’s Official Journal.
This publication opens the door for patent and brand protection, which the company expects will result in eventual sales through Indian distributors.
“The patent and trademark publications in India represent one of the more significant international market opportunities for Nyloxin,” Rik J. Deitsch, chairman and CEO of Nutra Pharma stated in the press release. “Now that we have patent protection to protect our formulas and trademark protection to defend the brand we can work to create sales and distribution in India. With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India represents a potentially significant customer base for Nyloxin.”
Nyloxin is currently available in the United States as an over-the-counter oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. Additionally, Nyloxin is offered in an extra strength formula for advanced chronic pain.
The patent entitled, “Use of Cobratoxin as an Analgesic,” was published in the Official Journal No.: 09/2013 of the Indian Patent Office (IPO) on March 1, 2013.
For more information, visit www.NutraPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
This publication opens the door for patent and brand protection, which the company expects will result in eventual sales through Indian distributors.
“The patent and trademark publications in India represent one of the more significant international market opportunities for Nyloxin,” Rik J. Deitsch, chairman and CEO of Nutra Pharma stated in the press release. “Now that we have patent protection to protect our formulas and trademark protection to defend the brand we can work to create sales and distribution in India. With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India represents a potentially significant customer base for Nyloxin.”
Nyloxin is currently available in the United States as an over-the-counter oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. Additionally, Nyloxin is offered in an extra strength formula for advanced chronic pain.
The patent entitled, “Use of Cobratoxin as an Analgesic,” was published in the Official Journal No.: 09/2013 of the Indian Patent Office (IPO) on March 1, 2013.
For more information, visit www.NutraPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Peter J. Goldstein Announced as Chairman of Staffing 360 Solutions, Inc. (STAF)
Staffing 360 Solutions, an emerging growth public company engaged in the provision of international staffing services in IT, financial, accounting, healthcare, and banking industries, today announced that the company has elected Peter J. Goldstein as Chairman of the Board of Directors of the company. Allan Hartley, Chief Executive Officer for Staffing 360 Solutions, made the announcement, noting that in addition to Mr. Goldstein’s position as Chairman, he also assumes the position of Treasurer and Secretary of the company.
“Peter Goldstein is a world class M&A executive whose advisory activities to date on behalf of the company have been enormously effective,” said Mr. Hartley. “We believe that his more active involvement as Chairman will accelerate the execution of our consolidation strategies, both in the U.S. and internationally.”
With over 25 years of experience, Mr. Goldstein is a seasoned financier and entrepreneur and has held the positions of chief architect, placement agent, and Investment Banker with extensive domestic, international, and multinational cross border M&A activity and capital raises throughout his career. Mr. Goldstein has actively participated in capital formation, including initial public offerings (IPO), alternative public offerings (APO), and private placements by effectively raising funds for companies in diverse industries by utilizing his strengths in M&A, strategic planning, and transaction structuring. He is also currently Principal and Co-Founder of TRIG Capital Group. Additionally, Mr. Goldstein is the founder, Chairman and CEO of Grandview Capital Partners, Inc., operating as an office of supervisory jurisdiction at Blackwall Capital Markets, Inc., a FINRA registered Broker Dealer and investment bank.
A.J. Cervantes, President of Staffing 360 Solutions, stated, “I have known Peter in a number of capacities over the last several years. First as Chairman of Grandview, and more recently as Co-Founder with me of TRIG Capital Group, our burgeoning private equity firm. With a broad array of strengths ranging from financial architect and innovative financier to an extraordinary work ethic and team builder, he is the kind of executive with the strength, experience and intelligence who can drive the company’s worldwide growth.”
“It is clear to me that Staffing 360 Solutions has the potential to become a preeminent force in the staffing industry in the U.S. and internationally,” commented Mr. Goldstein. “Working side-by-side with the senior management of Staffing 360 I look forward to executing the pipeline of accretive acquisitions we have developed to date and positioning Staffing 360 Solutions as an emerging growth public company that can deliver superior results as part of our commitment to growth in revenue, earnings and, ultimately, shareholder value.”
Initially launching is career as an entrepreneur, Mr. Goldstein has served as a Director, Chief Executive Officer, Advisor and consultant to public, private, and emerging companies within the United States and international markets since 1996. He holds an MBA in International Business which he obtained from the University of Miami, and currently has his 7, 24, 79, 99 and 66 registrations with FINRA. Mr. Goldstein is also a member of the National Investment Banking Association.
For more information on Staffing 360 Solutions, visit www.staffing360solutions.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“Peter Goldstein is a world class M&A executive whose advisory activities to date on behalf of the company have been enormously effective,” said Mr. Hartley. “We believe that his more active involvement as Chairman will accelerate the execution of our consolidation strategies, both in the U.S. and internationally.”
With over 25 years of experience, Mr. Goldstein is a seasoned financier and entrepreneur and has held the positions of chief architect, placement agent, and Investment Banker with extensive domestic, international, and multinational cross border M&A activity and capital raises throughout his career. Mr. Goldstein has actively participated in capital formation, including initial public offerings (IPO), alternative public offerings (APO), and private placements by effectively raising funds for companies in diverse industries by utilizing his strengths in M&A, strategic planning, and transaction structuring. He is also currently Principal and Co-Founder of TRIG Capital Group. Additionally, Mr. Goldstein is the founder, Chairman and CEO of Grandview Capital Partners, Inc., operating as an office of supervisory jurisdiction at Blackwall Capital Markets, Inc., a FINRA registered Broker Dealer and investment bank.
A.J. Cervantes, President of Staffing 360 Solutions, stated, “I have known Peter in a number of capacities over the last several years. First as Chairman of Grandview, and more recently as Co-Founder with me of TRIG Capital Group, our burgeoning private equity firm. With a broad array of strengths ranging from financial architect and innovative financier to an extraordinary work ethic and team builder, he is the kind of executive with the strength, experience and intelligence who can drive the company’s worldwide growth.”
“It is clear to me that Staffing 360 Solutions has the potential to become a preeminent force in the staffing industry in the U.S. and internationally,” commented Mr. Goldstein. “Working side-by-side with the senior management of Staffing 360 I look forward to executing the pipeline of accretive acquisitions we have developed to date and positioning Staffing 360 Solutions as an emerging growth public company that can deliver superior results as part of our commitment to growth in revenue, earnings and, ultimately, shareholder value.”
Initially launching is career as an entrepreneur, Mr. Goldstein has served as a Director, Chief Executive Officer, Advisor and consultant to public, private, and emerging companies within the United States and international markets since 1996. He holds an MBA in International Business which he obtained from the University of Miami, and currently has his 7, 24, 79, 99 and 66 registrations with FINRA. Mr. Goldstein is also a member of the National Investment Banking Association.
For more information on Staffing 360 Solutions, visit www.staffing360solutions.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Advaxis, Inc. (ADXS) to Present at SITC Cancer Immunotherapy Clinical Trials Workshop
Advaxis, a leading developer of the next generation of immunotherapies for cancer and infectious diseases, announced today that an abstract has been accepted for oral presentation at The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Clinical Trials: Concepts and Challenges workshop being held next week at the National Institutes of Health Campus (Masur Auditorium) in Bethesda, MD.
The abstract titled “Early Therapeutic Cancer Vaccine Clinical Trial Development” will be presented on April 4 at 10:30 am during Session 1 by Dr. Robert Petit, VP of Clinical Development and Medical Affairs at Advaxis. Dr. Petit will describe Advaxis’ experience with conducting early clinical trials with therapeutic Lm-LLO immunotherapies.
“The selection of our abstract for presentation at SITC provides an opportunity for Advaxis to share our experience in introducing Lm-LLO immunotherapy in a global clinical trial setting where there is great medical need,” stated Dr. Petit. “We are working toward a future when immunotherapy can fully take its place alongside conventional treatments in the global battle against cancer.”
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The abstract titled “Early Therapeutic Cancer Vaccine Clinical Trial Development” will be presented on April 4 at 10:30 am during Session 1 by Dr. Robert Petit, VP of Clinical Development and Medical Affairs at Advaxis. Dr. Petit will describe Advaxis’ experience with conducting early clinical trials with therapeutic Lm-LLO immunotherapies.
“The selection of our abstract for presentation at SITC provides an opportunity for Advaxis to share our experience in introducing Lm-LLO immunotherapy in a global clinical trial setting where there is great medical need,” stated Dr. Petit. “We are working toward a future when immunotherapy can fully take its place alongside conventional treatments in the global battle against cancer.”
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VIASPACE, Inc. (VSPC) Insiders Extend Lock-up of Shares
Today before the opening bell, VIASPACE announced that its Board of Directors agreed to extend the lock-up of their VIASPACE common stock shares for an additional 90 days, through June 30, 2013. VIASPACE CFO, Mr. Stephen Muzi; Director of Communications, Dr. Jan Vandersande; and Director of Social Media Outreach, Ms. Jaclyn Kenner, also decided to lock-up their VSPC common shares through June 30, 2013. The approximate number of shares involved in the lock-up extension totals 240,000,000.
“The VIASPACE Board and Management have been extremely pleased with the performance of VIASPACE since becoming a free-standing company on October 1, 2012,” stated Dr. Schewe. “At that time, we announced a 6-month lock-up of insider share sales. Given the pace of our corporate progress and the momentum that we have achieved, we felt it important to continue the lock-up for another 90 days as we work hard to continue to increase the scope of our general shareholder base of investors. In addition, Dr. Kukkonen has two significant foreign trips to meet with clients in April and we are looking forward to sharing the news of those trips and providing exciting updates on existing projects in the near future.”
For more information, visit www.viaspace.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“The VIASPACE Board and Management have been extremely pleased with the performance of VIASPACE since becoming a free-standing company on October 1, 2012,” stated Dr. Schewe. “At that time, we announced a 6-month lock-up of insider share sales. Given the pace of our corporate progress and the momentum that we have achieved, we felt it important to continue the lock-up for another 90 days as we work hard to continue to increase the scope of our general shareholder base of investors. In addition, Dr. Kukkonen has two significant foreign trips to meet with clients in April and we are looking forward to sharing the news of those trips and providing exciting updates on existing projects in the near future.”
For more information, visit www.viaspace.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Rainbow Coral Corp. (RBCC) Shares Excitement as TheraKine Joint Venture Moves Forward
Rainbow Coral this morning told investors that it is already searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out. TheraKline, developer of a revolutionary drug delivery platform that could soon make local delivery of biologic agents and small molecules safer and more effective, joint ventured with RBCC’s biotech subsidiary very recently.
As noted in today’s press release, the global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. It is believed by some experts that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion in just two years.
Working hard to maximize the success of its latest partnership, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” stated RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”
For more information on RBCC’s initiatives, visit www.rainbowbiosciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
As noted in today’s press release, the global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. It is believed by some experts that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion in just two years.
Working hard to maximize the success of its latest partnership, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” stated RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”
For more information on RBCC’s initiatives, visit www.rainbowbiosciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
International Stem Cell Corp. (ISCO) Schedules Conference Call to Discuss Financial Results and Update Investors
International Stem Cell Corp., a biotechnology company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), today announced that it will be hosting a conference call this week to discuss its 2012 financial results as well as provide a business update.
Dr. Simon Craw, Executive Vice President, and Ms. Linh Nguyen, Chief Financial Officer of International Stem Cell, will host the conference call. Those who wish to participate should use the dial-in information below.
Date: Thursday March 28, 2013
Time: 11:00 a.m. ET
Conference Line (U.S.): 1-877-941-2068
International Dial-In: 1-480-629-9712
Conference ID: 4610666
Webcast: http://public.viavid.com/player/index.php?id=104040
ISCO recommends logging in at least 10 minutes before the call start time. A playback of the call will be available shortly after its conclusion. Replay information can be found below.
Teleconference Replay Details:
US Domestic: 1-877-870-5176
International: 1-858-384-5517
Conference ID: 4610666
To learn more about International Stem Cell Corp., visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Dr. Simon Craw, Executive Vice President, and Ms. Linh Nguyen, Chief Financial Officer of International Stem Cell, will host the conference call. Those who wish to participate should use the dial-in information below.
Date: Thursday March 28, 2013
Time: 11:00 a.m. ET
Conference Line (U.S.): 1-877-941-2068
International Dial-In: 1-480-629-9712
Conference ID: 4610666
Webcast: http://public.viavid.com/player/index.php?id=104040
ISCO recommends logging in at least 10 minutes before the call start time. A playback of the call will be available shortly after its conclusion. Replay information can be found below.
Teleconference Replay Details:
US Domestic: 1-877-870-5176
International: 1-858-384-5517
Conference ID: 4610666
To learn more about International Stem Cell Corp., visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, March 25, 2013
ZaZa Energy Corp. (ZAZA) Secures Huge Joint Venture Deal, Immediate Development on Eaglebine
ZaZa Energy, the Houston-based E&P with a combined 92k net acre footprint smack in the heart of the Texas Eagle Ford/Eaglebine plays, reported inking a major joint exploration and development agreement today aimed at developing the Eaglebine assets, in conjunction with one of the top independent crude oil and natural gas firms in the U.S.
This is a sizeable agreement and will allow ZAZA to jump start development on the highly prospective land, with the JV partner acquiring as much as 75% WI in 55k net acres and ultimately being responsible for operating the 73k total net acres covered under the JV (ZAZA retains 25% on these lands). The wholly-owned lands covered by the agreement include those inside Grimes, Madison, Montgomery, Trinity, and Walker counties. Also among the acreage in this deal are certain lands covered under the participation agreement with Range Resources Corp. wholly-owned subsidiary, Range Texas Production, LLC.
President and CEO of ZAZA, Todd Brooks, beamed with excitement at the prospect of partnering like this with one of the biggest unconventional and oil-focused operators going. Brooks boldly pointed to how the realization of this deal underwrites the company’s Eaglebine work program thus far and further emphasized how the JV will accelerate near-term production and introduce economies of scale to the development/production envelope, also confirming to markets that initial phases would focus heavily on optimization of oilfield development.
With early-stage Phase I drilling already well underway on the first two JV wells, ZAZA is looking forward to capitalizing on this dynamic new JV and confidence is high that the undisclosed partner will have drilled the first three earning wells by January of next year. Plans for development are currently broken up into three phases, each one marked by a three-well punch and associated cash payments, with the second two phases being elective and according to the JV partner’s discretion upon satisfaction of work obligations in the preceding phase(s).
ZAZA’s utilization of a robust battery of advanced analytical tools helped land this deal. Fusing together open-hole logging, integrated core/sample lab data, and micro-seismic methodologies to drive rich 3D mapping and design/viz efforts. The company goes beyond extensive review of formation sampling and rock analysis, right to the bleeding-edge of the most innovative tech in the industry today. Top shelf resource visualization is about to come together with leading industry development muscle through this JV and markets will be chomping at the bit to get a look at upcoming well data on the Eaglebine properties.
Solid move really, post the sale of the company’s French assets to Vermilion Energy Inc. (Dec 27, 2012). ZAZA is now able to focus on their exceptional position in Texas from a much better balance sheet position, armed with better capitalization and the confidence that comes from having paid down over two-thirds of the company’s senior secured debt in less than a year.
For more information on ZaZa Energy, visit www.ZaZaEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
This is a sizeable agreement and will allow ZAZA to jump start development on the highly prospective land, with the JV partner acquiring as much as 75% WI in 55k net acres and ultimately being responsible for operating the 73k total net acres covered under the JV (ZAZA retains 25% on these lands). The wholly-owned lands covered by the agreement include those inside Grimes, Madison, Montgomery, Trinity, and Walker counties. Also among the acreage in this deal are certain lands covered under the participation agreement with Range Resources Corp. wholly-owned subsidiary, Range Texas Production, LLC.
President and CEO of ZAZA, Todd Brooks, beamed with excitement at the prospect of partnering like this with one of the biggest unconventional and oil-focused operators going. Brooks boldly pointed to how the realization of this deal underwrites the company’s Eaglebine work program thus far and further emphasized how the JV will accelerate near-term production and introduce economies of scale to the development/production envelope, also confirming to markets that initial phases would focus heavily on optimization of oilfield development.
With early-stage Phase I drilling already well underway on the first two JV wells, ZAZA is looking forward to capitalizing on this dynamic new JV and confidence is high that the undisclosed partner will have drilled the first three earning wells by January of next year. Plans for development are currently broken up into three phases, each one marked by a three-well punch and associated cash payments, with the second two phases being elective and according to the JV partner’s discretion upon satisfaction of work obligations in the preceding phase(s).
ZAZA’s utilization of a robust battery of advanced analytical tools helped land this deal. Fusing together open-hole logging, integrated core/sample lab data, and micro-seismic methodologies to drive rich 3D mapping and design/viz efforts. The company goes beyond extensive review of formation sampling and rock analysis, right to the bleeding-edge of the most innovative tech in the industry today. Top shelf resource visualization is about to come together with leading industry development muscle through this JV and markets will be chomping at the bit to get a look at upcoming well data on the Eaglebine properties.
Solid move really, post the sale of the company’s French assets to Vermilion Energy Inc. (Dec 27, 2012). ZAZA is now able to focus on their exceptional position in Texas from a much better balance sheet position, armed with better capitalization and the confidence that comes from having paid down over two-thirds of the company’s senior secured debt in less than a year.
For more information on ZaZa Energy, visit www.ZaZaEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Channel Marketing Plan of GlobalWise Investments, Inc. (GWIV)
GlobalWise Investments, provider of ECM (Enterprise Content Management) systems to businesses and organizations through its subsidiary Intellinetics, has a stated goal of moving away from direct sales into a channel sales orientation. As such, Intellinetics is always interested in finding qualified partners looking to add value to their own offerings by incorporating the Intellivue electronic content management solution.
Intellinetics solutions are already serving a diverse collection of industries, such as education, healthcare, automotive, government, retail, and financial services, and the company is aware of the unique requirements every industry has when it comes to automated records management. To address this, the company supports reseller partners in a variety of ways to best get the appropriate message out to customers, including the following:
• Customer calls (on-site and via WebEx) – Each partner/reseller is assigned their own experienced Intellinetics Business Development Manager for assistance and help on customer calls and WebEx’s.
• Weekly WebEx General Knowledge and Demo Sessions – Webinars can be set up and made available to a partner’s client base, showing Intellivue’s advantages and addressing particular customer needs.
• Telemarketing Campaigns – Telemarketing scripts and questions to ask during telemarketing campaigns and calls are provided by Intellinetics for assistance and as guidelines.
• Web Marketing Campaigns – Intellinetics information, including Intellinetics related news and events, can be set up on a partner’s website.
• Email Marketing – Intellinetics provides information, ads, and additional cobranded material that partners can use to launch powerful email marketing campaigns.
• Trade Shows – Intellinetics Business Development Managers are available to attend and speak at trade shows, customer events, and/or open houses hosted for clients.
Intellinetics can also provide direct sales rep support and coaching, weekly status calls, and even demonstration software, all to help partners get the most out of their relationship with Intellinetics.
For additional information on GlobalWise and its subsidiary, Intellinetics, visit www.GlobalWiseInvestments.com and www.Intellinetics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Intellinetics solutions are already serving a diverse collection of industries, such as education, healthcare, automotive, government, retail, and financial services, and the company is aware of the unique requirements every industry has when it comes to automated records management. To address this, the company supports reseller partners in a variety of ways to best get the appropriate message out to customers, including the following:
• Customer calls (on-site and via WebEx) – Each partner/reseller is assigned their own experienced Intellinetics Business Development Manager for assistance and help on customer calls and WebEx’s.
• Weekly WebEx General Knowledge and Demo Sessions – Webinars can be set up and made available to a partner’s client base, showing Intellivue’s advantages and addressing particular customer needs.
• Telemarketing Campaigns – Telemarketing scripts and questions to ask during telemarketing campaigns and calls are provided by Intellinetics for assistance and as guidelines.
• Web Marketing Campaigns – Intellinetics information, including Intellinetics related news and events, can be set up on a partner’s website.
• Email Marketing – Intellinetics provides information, ads, and additional cobranded material that partners can use to launch powerful email marketing campaigns.
• Trade Shows – Intellinetics Business Development Managers are available to attend and speak at trade shows, customer events, and/or open houses hosted for clients.
Intellinetics can also provide direct sales rep support and coaching, weekly status calls, and even demonstration software, all to help partners get the most out of their relationship with Intellinetics.
For additional information on GlobalWise and its subsidiary, Intellinetics, visit www.GlobalWiseInvestments.com and www.Intellinetics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wave Systems Corp. (WAVX) Division Selected by Florida Peninsula Insurance to Automate Insurance Processes for Agents and Consumers
Today, eSignSystems, a division of Wave Systems, announced that Florida Peninsula Insurance (FPI) will be integrating its signing and management technology. This decision will directly benefit both independent agents and consumer policy holders served by Florida Peninsula, enabling them to remotely review, sign, and administrate policies from any convenient location. FPI will also receive the benefit of full electronic capture and document access, which will streamline compliance with changing insurance regulations and ensure the speediest response when policyholders are filing claims.
FPI has become one of Florida’s largest homeowner insurers since the company was founded in 2005. FPI serves more than 140,000 policyholders, and in a challenging industry and a state that is prone to hurricanes, the company credits its growth and success to a dedicated approach of partnering with independent agents and policyholders. The company is dedicated to meeting the needs of agents and policyholders and investing in its people and technology to continually improve insurance.
The implementation of eSignSystems’ SmartSAFE will enable electronic signatures that are faster, legally binding and securely delivered, which will resultantly reduce costs and processing time for online insurance application submissions, streamline underwriting, and speed up claims processing for consumers. Independent agents will be able to remotely sign and complete insurance policies from the office or a client’s home – thereby maximizing the use of tablets and laptops. Agents will gain improved document integrity and simultaneously reduce repetitive data re-keying and the tedious review of illegible faxes.
“Our partnership with eSignSystems provides excellent technology for our agents and insureds,” said FPI Director of Operations Chris Chandler. “To get a policy, file a claim or make changes to a policy all from the comfort of your home fits well with our pledge to provide fast, fair and friendly service. We continually strive to raise the technology bar, and our network of independent agents appreciate the ease of doing business with Florida Peninsula. With electronic signature, agents will gain additional efficiencies and make doing business with us that much easier.”
FPI’s transition to electronic document signing and management is further strengthened by the company’s policy administration system, which provides full e-document management throughout the life of a policy, including secure transmission and storage of the signed and completed document within easy searching capabilities of FPI’s policy administration system. This enables easy claims access without the need to search a warehouse or independent agent file cabinets, and it also provides a complete audit trail for proof of compliance as well as flexibility to adapt to new regulations in an industry that continues to improve its governance.
For more information, visit www.esignsystems.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
FPI has become one of Florida’s largest homeowner insurers since the company was founded in 2005. FPI serves more than 140,000 policyholders, and in a challenging industry and a state that is prone to hurricanes, the company credits its growth and success to a dedicated approach of partnering with independent agents and policyholders. The company is dedicated to meeting the needs of agents and policyholders and investing in its people and technology to continually improve insurance.
The implementation of eSignSystems’ SmartSAFE will enable electronic signatures that are faster, legally binding and securely delivered, which will resultantly reduce costs and processing time for online insurance application submissions, streamline underwriting, and speed up claims processing for consumers. Independent agents will be able to remotely sign and complete insurance policies from the office or a client’s home – thereby maximizing the use of tablets and laptops. Agents will gain improved document integrity and simultaneously reduce repetitive data re-keying and the tedious review of illegible faxes.
“Our partnership with eSignSystems provides excellent technology for our agents and insureds,” said FPI Director of Operations Chris Chandler. “To get a policy, file a claim or make changes to a policy all from the comfort of your home fits well with our pledge to provide fast, fair and friendly service. We continually strive to raise the technology bar, and our network of independent agents appreciate the ease of doing business with Florida Peninsula. With electronic signature, agents will gain additional efficiencies and make doing business with us that much easier.”
FPI’s transition to electronic document signing and management is further strengthened by the company’s policy administration system, which provides full e-document management throughout the life of a policy, including secure transmission and storage of the signed and completed document within easy searching capabilities of FPI’s policy administration system. This enables easy claims access without the need to search a warehouse or independent agent file cabinets, and it also provides a complete audit trail for proof of compliance as well as flexibility to adapt to new regulations in an industry that continues to improve its governance.
For more information, visit www.esignsystems.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Loans4Less.com, Inc. (LFLS) Champions the Customer
Borrowers go to Loans4Less.com, a growing California-based online mortgage loan brokerage, for easy to access loan and related real estate information, but primarily for the company’s advertised interest rates and closing costs. Since Loans4Less deals with many wholesale lending institutions, they can put together a range of mortgage products to suit the needs of the customer.
But the company’s real strength is that it has integrated the sometimes complex world of residential mortgage loans into an online environment in such a way as to create an attractive platform with compelling options for joint venture and licensing partners as well as for end consumers. It’s an approach that is highly cost effective, providing the leeway for the company to offer flexible packages that are especially attractive to low interest rate seekers. At the same time, Loans4Less is also up-front about risks and the need for careful evaluation, representing an openness and dependability that attracts new buyers.
An example is the company’s “Lock and Float Down Policy”. Depending upon what the borrower is looking for, Loans4Less is able to lock in interest rates. It sounds good, but rates can go down as well as up. To deal with this, the company can seek to “re-lock” a loan with a different lender in order to obtain better terms. However, in times of high-volume or volatile markets, they may advise the borrower not to adjust the original rate lock, avoiding the risk of gambling for a marginally lower rate that may not materialize. They also point out that current mortgage industry practices prohibit the use of appraisal reports derived from a different lender or third party. So, if a loan is cancelled in order to resubmit to a different lender to obtain a lower “float down” rate, it may end up requiring an additional appraisal and associated fee.
It’s this concern for open communication and the application of experience to protect the customer that is especially important to prospective borrowers, coming out of a real estate market where many were burned by careless practices.
For more information, visit www.Loans4Less.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
But the company’s real strength is that it has integrated the sometimes complex world of residential mortgage loans into an online environment in such a way as to create an attractive platform with compelling options for joint venture and licensing partners as well as for end consumers. It’s an approach that is highly cost effective, providing the leeway for the company to offer flexible packages that are especially attractive to low interest rate seekers. At the same time, Loans4Less is also up-front about risks and the need for careful evaluation, representing an openness and dependability that attracts new buyers.
An example is the company’s “Lock and Float Down Policy”. Depending upon what the borrower is looking for, Loans4Less is able to lock in interest rates. It sounds good, but rates can go down as well as up. To deal with this, the company can seek to “re-lock” a loan with a different lender in order to obtain better terms. However, in times of high-volume or volatile markets, they may advise the borrower not to adjust the original rate lock, avoiding the risk of gambling for a marginally lower rate that may not materialize. They also point out that current mortgage industry practices prohibit the use of appraisal reports derived from a different lender or third party. So, if a loan is cancelled in order to resubmit to a different lender to obtain a lower “float down” rate, it may end up requiring an additional appraisal and associated fee.
It’s this concern for open communication and the application of experience to protect the customer that is especially important to prospective borrowers, coming out of a real estate market where many were burned by careless practices.
For more information, visit www.Loans4Less.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
